New research has shown that infliximab clearance is increased in patients hospitalized with severe ulcerative colitis, potentially leading to a higher risk of underexposure when standard dosing regimens are used. The study, which analyzed infliximab pharmacokinetics in 154 patients with ulcerative colitis, found that patients who were hospitalized exhibited a 35% increase in infliximab clearance compared to outpatients (0.463 L/day vs. 0.339 L/day, p<0.0001). This resulted in subtherapeutic drug levels in the majority of patients from week 2 onwards, with 74% of hospitalized patients having infliximab concentrations below 20 µg/mL at week 2, 69% below 15 µg/mL at week 6, and 56% below 7 µg/mL at week 14.

New findings from the VIVID-2 study, presented at the 20th Congress of ECCO, support the sustained efficacy of mirikizumab, an interleukin-23p19 inhibitor, in patients with moderate-to-severe Crohn’s disease previously treated with ustekinumab. In this open-label extension of the Phase III VIVID-1 trial, patients were switched to mirikizumab, with dosing based on their endoscopic response status at week 52 of VIVID-1.

Itolizumab, an investigational anti-CD6 monoclonal antibody, has shown promising results in a phase II clinical trial for patients with moderate to severe ulcerative colitis. Designed to target the CD6-ALCAM pathway, a mechanism implicated in gastrointestinal inflammation, itolizumab was reported to achieve clinical remission rates comparable to adalimumab.

To gain expert insight into the most impactful developments of the past year and the trends set to shape the next, we reached out to our esteemed expert faculty. From advances in targeted therapies to the integration of AI and ...

Medics4RareDiseases is evolving. We are excited to announce a refresh of our strategy, a relaunch of our branding and even a new name! The charity has grown beyond our highest expectations over the last five years. With this in ...

A globally recognized allergologist specializing in urticaria, drug allergies, and angioedema, Professor Luis FC Ensina has significantly advanced clinical care, research, and education. As a Professor at the Federal University of São Paulo and coordinator of its specialized outpatient clinic, he leads Alergoalpha, a Center of Excellence for UCARE, ACARE, and ADCARE, where he has overseen over 20 clinical trials and authored more than 100 publications. A founder of the Brazilian Urticaria Network (RUBRA) and co-author of international urticaria guidelines, he has played a pivotal role in shaping global standards for allergy care. Active in organizations such as GA2LEN, AAAAI, and EAACI, he highlights the transformative potential of emerging therapies, gene therapy, and artificial intelligence to redefine allergy and immunology practice worldwide.

Prof. Paul Fockens, recipient of the 2024 UEG Lifetime Achievement Award, has profoundly shaped the field of gastrointestinal endoscopy. From pioneering techniques like endoscopic ultrasound to advancing colorectal cancer screening and minimally invasive surgeries, his transformative contributions have improved patient care globally. A dedicated mentor and leader, Prof. Fockens has also championed education and innovation through his work with UEG and beyond."

Join us as we unveil the content that made the greatest impact in 2024. From insightful Q&As and news articles to engaging podcasts, conference highlights, and medical education resources, this year has been filled with valuable content designed to support your daily practice and, ultimately, enhance patient care.

Recent advancements made in understanding the pathology of inflammatory skin conditions have enabled JAK inhibitors, initially developed for haematology over 20 years ago, to be investigated for dermatological use. In this episode, Dr William (Bill) Damsky discusses JAK inhibitors’ journey from proof-of-concept to treating a wide range of skin conditions, their future impact on rare diseases and the debate around safety.